JMW-3B3 

JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.^[1][2]

Human

Biotinylated JMW-3B3 (10 μg/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides^[1].
JMW-3B3 (10 μg/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups^[1].
JMW-3B3 (20 μg/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells^[2].
JMW-3B3 (10 μg/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 μg/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment^[2].
JMW-3B3 (10 μg/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 μg/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1493  [NCBI]

P16410

CTLA4

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[JMW-3B3]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dahal LN, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18:180. Published 2016 Aug 4.  [Content Brief]

  [2]. Khanolkar RC, et al. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front Immunol. 2022;12:763877. Published 2022 Jan 5.  [Content Brief]